Literature DB >> 14603445

Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia.

Joris Andrieux1, Jean-Loup Demory, Brigitte Dupriez, Sabine Quief, Isabelle Plantier, Christophe Roumier, Francis Bauters, Jean Luc Laï, Jean-Pierre Kerckaert.   

Abstract

Among cytogenetic studies of patients affected with myelofibrosis with myeloid metaplasia (MMM), a rare chronic myeloproliferative disorder, we found several reports of structural abnormalities of the long arm of chromosome 12. Two MMM patients had a balanced translocation involving 12q: t(4;12)(q32;q15) and t(5;12)(p14;q15), respectively. FISH (fluorescence in situ hybridization) analysis showed that BAC (bacterial artificial chromosome) RP11-366L20 overlaps the breakpoint in both cases. A gene, HMGA2, most of which is included in that BAC, thus was identified as a potential candidate. Using reserves transcriptase-polymerase chain reaction (RT-PCR), we looked for expression of HMGA2 in blood mononuclear cells from these 2 patients and demonstrated a transcript in both. Moreover, we found the gene expressed in the hematopoietic cells of 10 of 10 additional patients bearing no 12q anomalies. HMGA2, not expressed in normal subjects, is implicated in benign solid tumors such as lipomas, leiomyomas, and other rare tumors of mesenchymal origin. We postulate that its dysregulation and overexpression in myeloid progenitors contribute also to the pathogenesis of MMM. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14603445     DOI: 10.1002/gcc.10297

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  13 in total

1.  Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.

Authors:  Bridget K Marcellino; Ronald Hoffman; Joseph Tripodi; Min Lu; Heidi Kosiorek; John Mascarenhas; Raajit K Rampal; Amylou Dueck; Vesna Najfeld
Journal:  Blood Adv       Date:  2018-12-26

2.  Constitutional rearrangement of the architectural factor HMGA2: a novel human phenotype including overgrowth and lipomas.

Authors:  Azra H Ligon; Steven D P Moore; Melissa A Parisi; Matthew E Mealiffe; David J Harris; Heather L Ferguson; Bradley J Quade; Cynthia C Morton
Journal:  Am J Hum Genet       Date:  2004-12-10       Impact factor: 11.025

3.  HMGI-C suppressing induces P53/caspase9 axis to regulate apoptosis in breast adenocarcinoma cells.

Authors:  Behzad Mansoori; Ali Mohammadi; Solmaz Shirjang; Behzad Baradaran
Journal:  Cell Cycle       Date:  2016-05-31       Impact factor: 4.534

4.  Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms.

Authors:  Koki Ueda; Kazuhiko Ikeda; Takayuki Ikezoe; Kayo Harada-Shirado; Kazuei Ogawa; Yuko Hashimoto; Takahiro Sano; Hiroshi Ohkawara; Satoshi Kimura; Akiko Shichishima-Nakamura; Yuichi Nakamura; Yayoi Shikama; Tsutomu Mori; Philip J Mason; Monica Bessler; Soji Morishita; Norio Komatsu; Kotaro Shide; Kazuya Shimoda; Shuhei Koide; Kazumasa Aoyama; Motohiko Oshima; Atsushi Iwama; Yasuchika Takeishi
Journal:  Blood Adv       Date:  2017-06-14

5.  Silencing of High Mobility Group Isoform I-C (HMGI-C) Enhances Paclitaxel Chemosensitivity in Breast Adenocarcinoma Cells (MDA-MB-468).

Authors:  Behzad Mansoori; Ali Mohammadi; Samira Goldar; Dariush Shanehbandi; Leila Mohammadnejad; Elham Baghbani; Tohid Kazemi; Saeed Kachalaki; Behzad Baradaran
Journal:  Adv Pharm Bull       Date:  2016-06-30

6.  3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice.

Authors:  Kazuhiko Ikeda; Philip J Mason; Monica Bessler
Journal:  Blood       Date:  2011-04-01       Impact factor: 22.113

7.  Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm.

Authors:  Yue Yang; Hajime Akada; Dipmoy Nath; Robert E Hutchison; Golam Mohi
Journal:  Blood       Date:  2016-04-14       Impact factor: 22.113

8.  Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes.

Authors:  Hideyuki Oguro; Jin Yuan; Satomi Tanaka; Satoru Miyagi; Makiko Mochizuki-Kashio; Hitoshi Ichikawa; Satoshi Yamazaki; Haruhiko Koseki; Hiromitsu Nakauchi; Atsushi Iwama
Journal:  J Exp Med       Date:  2012-02-20       Impact factor: 14.307

9.  Hmga2 promotes the development of myelofibrosis in Jak2V617F knockin mice by enhancing TGF-β1 and Cxcl12 pathways.

Authors:  Avik Dutta; Robert E Hutchison; Golam Mohi
Journal:  Blood       Date:  2017-06-21       Impact factor: 22.113

10.  Molecular deregulation induced by silencing of the high mobility group protein A2 gene in retinoblastoma cells.

Authors:  Nalini Venkatesan; Subramanian Krishnakumar; Perinkulam Ravi Deepa; Murali Deepa; Vikas Khetan; M Ashwin Reddy
Journal:  Mol Vis       Date:  2012-10-03       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.